Yip-Schneider MT - Search Results

1

Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.

Yip-Schneider MT, Wiesenauer CA, Schmidt CM. Yip-Schneider MT, et al. J Gastrointest Surg. 2003 Mar-Apr;7(3):354-63. doi: 10.1016/s1091-255x(02)00156-7. J Gastrointest Surg. 2003. PMID: 12654560

2

Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.

Yip-Schneider MT, Lin A, Marshall MS. Yip-Schneider MT, et al. Biochem Biophys Res Commun. 2001 Feb 2;280(4):992-7. doi: 10.1006/bbrc.2001.4243. Biochem Biophys Res Commun. 2001. PMID: 11162624

3

Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.

Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Yip-Schneider MT, et al. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85. J Pharmacol Exp Ther. 2001. PMID: 11504793

4

MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.

Yip-Schneider MT, Schmidt CM. Yip-Schneider MT, et al. Pancreas. 2003 Nov;27(4):337-44. doi: 10.1097/00006676-200311000-00012. Pancreas. 2003. PMID: 14576498

5

Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.

Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Wiesenauer CA, et al. J Am Coll Surg. 2004 Mar;198(3):410-21. doi: 10.1016/j.jamcollsurg.2003.10.004. J Am Coll Surg. 2004. PMID: 14992744

6

Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.

Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM. Yip-Schneider MT, et al. Mol Cancer Ther. 2005 Apr;4(4):587-94. doi: 10.1158/1535-7163.MCT-04-0215. Mol Cancer Ther. 2005. PMID: 15827332

7

The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS. Klein PJ, et al. Neoplasia. 2006 Jan;8(1):1-8. doi: 10.1593/neo.05373. Neoplasia. 2006. PMID: 16533420 Free PMC article.

8

Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.

Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, Schmidt CM. Ralstin MC, et al. Mol Cancer Res. 2006 Jun;4(6):387-99. doi: 10.1158/1541-7786.MCR-05-0157. Mol Cancer Res. 2006. PMID: 16778086

9

Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

Crowell PL, Schmidt CM, Yip-Schneider MT, Savage JJ, Hertzler DA 2nd, Cummings WO. Crowell PL, et al. Neoplasia. 2006 Jun;8(6):437-45. doi: 10.1593/neo.04700. Neoplasia. 2006. PMID: 16820089 Free PMC article.

10

Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.

Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM. Yip-Schneider MT, et al. Mol Cancer Ther. 2007 Jun;6(6):1736-44. doi: 10.1158/1535-7163.MCT-06-0794. Epub 2007 May 31. Mol Cancer Ther. 2007. PMID: 17541034

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters